Hamel Associates’s AtriCure ATRC Stock Holding History

Hamel Associates’s Portfolio ATRC Stock Details ATRC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-3,200	Closed	-$210K	–	69
2021 Q1	$210K	Buy	+3,200	New	+$197K	0.08%	69

Other funds holding ATRC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Hamel Associates's ATRC Position: Q2 2021 in Review

Hamel Associates sold out of AtriCure (ATRC) in Q2 2021, closing a stake of 3,200 shares — an estimated $210K sold.

Hamel Associates first reported a position in ATRC in Q1 2021 and held it in 1 quarter. The position peaked at $210K in Q1 2021. 212 funds tracked by Wall St. Rank hold ATRC as of Q2 2021.

Hamel Associates reported no remaining AtriCure position as of Q2 2021 after selling out during the quarter.
Hamel Associates sold 3,200 AtriCure shares in Q2 2021, an estimated $210K.
Hamel Associates first reported a position in AtriCure in Q1 2021 and held it in 1 quarter.
Hamel Associates's AtriCure position peaked at $210K in Q1 2021.
212 funds tracked by Wall St. Rank held AtriCure as of Q2 2021.

Based on Hamel Associates's 13F filing for Q2 2021, filed 4 Aug 2021.